GASTROINTESTINAL DRUGS ADVISORY COMMITTEE

June 26, 2000

Slides

Zelmac (tegaserod) NDA 21-200

Introduction, Mathias Hukkelhoven, PhD, Novartis Pharmaceuticals Corporation   ppt   html

Overview of Irritable Bowel Syndrome, Arnold Wald, MD, University of Pittsburgh Medical Center   ppt   html

5-HT₄ Receptor Physiology and Pharmacodynamic Effects of Tegaserod, Michael Camilleri, MD, Mayo Clinic Foundation   ppt   html

Efficacy and Safety, Martin P Lefkowitz, MD, Novartis Pharmaceuticals Corporation   ppt   html

Preclinical Studies, Philip Bently PhD, Novartis Pharmaceuticals Corporation   ppt   html

Review of Ovarian Cysts, Bruce Carr MD, University of Texas Southwestern Medical Center   ppt   html

Conclusions, Sidney Cohen MD, Temple University School of Medicine   ppt   html

Statistical Considerations on NDA 21-200, Sonia Castillo PhD, FDA   ppt   html

Zelmac (tegaserod), Raymond E Joseph MD, FDA   ppt   html